Compare · Head-to-head
BPC-157 vs Cerebrolysin.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Cerebrolysin, then use the table to confirm fit.
Cerebrolysin is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
BPC-157
Preclinical cytoprotective peptide studied for tissue repair and GI protection in animal models.
01 · At a glance
| Decision factor | BPC-157 | Cerebrolysin |
|---|---|---|
| Primary fit | tissue repair & recovery research where you want a clear starting point | tissue repair & recovery and cognitive & neuroprotection comparisons |
| Evidence | Tier C | Tier C |
| Risk | med-high | medium |
| Experience level | intermediate | advanced |
| Budget tier | mid | premium |
| Administration route | subcutaneous, oral | intravenous, intramuscular |
02 · Use case & timing
| Decision factor | BPC-157 | Cerebrolysin |
|---|---|---|
| Goal fit | Tissue Repair & Recovery | Tissue Repair & Recovery, Cognitive & Neuroprotection |
| What users compare it for | Preclinical: angiogenesis markers, tissue repair signals, GI mucosal protection in rodent models. | Possible neurorecovery or cognitive-support effects in select clinical settings, though evidence quality is heterogeneous. |
| Onset timeline | Animal models: endpoints assessed over days to weeks (2-4 weeks in injury models). | Clinical outcomes are tracked over days to weeks in stroke or cognition programs. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | BPC-157 | Cerebrolysin |
|---|---|---|
| Adverse effects | Insufficient human data; immunogenicity risk flagged by FDA; impurity characterization concerns. | Headache, fever, nausea, restlessness, injection reactions, and rare hypersensitivity are reported. |
| Contraindications | No established human contraindications (insufficient data). | Use caution in porcine-protein sensitivity and where product provenance cannot be established. |
| Interaction notes | No robust human interaction map; avoid confident stacking claims. | No strong interaction map; combining with other CNS-active research compounds increases interpretation difficulty. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA compounding caution | FDA status unclear |
| WADA status | WADA S0 | Not listed |
04 · Age & monitoring
| Decision factor | BPC-157 | Cerebrolysin |
|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54, 55-64 | No age guidance yet |
| Life-stage note | Commonly researched by active adults for recovery, but still lacks validated human age-specific evidence. | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | BPC-157 | Cerebrolysin |
|---|---|---|
| Typical cycle cost | $118.99 | No reliable estimate yet |
| Estimated monthly cost | $79.32 | No reliable estimate yet |
| Cost confidence | High confidence | No estimate |
06 · Before you buy
| Decision factor | BPC-157 | Cerebrolysin |
|---|---|---|
| Tracked vendor listings | 3 listings | 0 listings |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | No tracked product page yet, so sourcing takes more manual review. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.